Cowen and Company restated their outperform rating on shares of Dynavax Technologies Corporation (NASDAQ:DVAX) in a research report released on Thursday morning. The firm currently has a $30.00 target price on the biopharmaceutical company’s stock.

Other research analysts have also recently issued reports about the stock. Zacks Investment Research raised shares of Dynavax Technologies Corporation from a hold rating to a buy rating and set a $11.00 price target on the stock in a research report on Monday, July 10th. Royal Bank Of Canada set a $7.00 target price on shares of Dynavax Technologies Corporation and gave the stock a hold rating in a research report on Wednesday, July 26th. BidaskClub cut shares of Dynavax Technologies Corporation from a buy rating to a hold rating in a research report on Monday, July 31st. William Blair reissued an outperform rating and set a $30.00 target price on shares of Dynavax Technologies Corporation in a research report on Wednesday. Finally, J P Morgan Chase & Co raised shares of Dynavax Technologies Corporation from a neutral rating to an overweight rating and boosted their target price for the stock from $6.00 to $27.00 in a research report on Monday, July 31st. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of $23.34.

Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) traded up 2.84% during trading on Thursday, hitting $16.30. 2,572,043 shares of the stock traded hands. The company’s 50 day moving average is $11.71 and its 200 day moving average is $7.12. Dynavax Technologies Corporation has a 52-week low of $3.20 and a 52-week high of $19.60. The firm’s market cap is $892.38 million.

Dynavax Technologies Corporation (NASDAQ:DVAX) last announced its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.09. The firm had revenue of $0.11 million for the quarter, compared to analysts’ expectations of $0.15 million. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 92.09%. During the same period in the previous year, the company posted ($0.75) earnings per share. On average, equities research analysts predict that Dynavax Technologies Corporation will post ($1.58) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Dynavax Technologies Corporation’s (NASDAQ:DVAX) Outperform Rating Reaffirmed at Cowen and Company” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/08/13/dynavax-technologies-corporations-nasdaqdvax-outperform-rating-reaffirmed-at-cowen-and-company.html.

Hedge funds have recently modified their holdings of the company. Renaissance Technologies LLC bought a new stake in shares of Dynavax Technologies Corporation during the fourth quarter worth about $1,833,000. Russell Investments Group Ltd. bought a new stake in shares of Dynavax Technologies Corporation during the fourth quarter worth about $317,000. Endurant Capital Management LP raised its stake in shares of Dynavax Technologies Corporation by 205.4% in the first quarter. Endurant Capital Management LP now owns 173,458 shares of the biopharmaceutical company’s stock worth $1,032,000 after buying an additional 116,658 shares during the period. Kornitzer Capital Management Inc. KS raised its stake in shares of Dynavax Technologies Corporation by 90.3% in the first quarter. Kornitzer Capital Management Inc. KS now owns 1,098,510 shares of the biopharmaceutical company’s stock worth $6,536,000 after buying an additional 521,310 shares during the period. Finally, Highbridge Capital Management LLC bought a new stake in shares of Dynavax Technologies Corporation during the first quarter worth about $513,000. Institutional investors and hedge funds own 56.05% of the company’s stock.

About Dynavax Technologies Corporation

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Receive News & Stock Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related stocks with our FREE daily email newsletter.